Avidity Biosciences (RNA) Announces Positive One-Year Data For its, Del-Zota

Core Insights - Avidity Biosciences, Inc. (NASDAQ:RNA) has been recognized as one of the best performing long-term stocks by analysts, following the announcement of positive one-year data for its del-zota treatment in trials for Duchenne muscular dystrophy patients [1] - The management highlighted that the data indicates a reversal of disease progression and significant functional improvements compared to baseline and natural history [2] Trial Results - Trial participants exhibited approximately a 25% increase in dystrophin levels and up to 58% restoration of total dystrophin levels [3] - Creatine kinase (CK), a muscle damage marker, decreased by over 80% and remained near normal levels [3] - Avidity Biosciences plans to submit a Biologics License Application (BLA) to the FDA by the end of 2025 for accelerated approval, representing a significant advancement in treatment options for this severe genetic condition [3] Company Overview - Avidity Biosciences is focused on developing a new class of RNA therapies known as Antibody Oligonucleotide Conjugates [4]